Scarica l'app Stockscreener
1.18
2.61%
0.03
Precedente Chiudi:
$1.15
Aprire:
$1.15
Volume 24 ore:
103.10K
Relative Volume:
0.57
Capitalizzazione di mercato:
$40.98M
Reddito:
$2.91M
Utile/perdita netta:
$-220.40M
Rapporto P/E:
-0.3242
EPS:
-3.64
Flusso di cassa netto:
$-176.15M
1 W Prestazione:
+4.42%
1M Prestazione:
-0.84%
6M Prestazione:
-87.54%
1 anno Prestazione:
-87.30%
Intervallo 1D:
$1.11
$1.20
Intervallo di 1 settimana:
$1.08
$1.225
Portata 52W:
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Nome
Igm Biosciences Inc
Settore
Industria
Telefono
650-965-7873
Indirizzo
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Confronta IGMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.18 | 67.86M | 2.91M | -220.40M | -176.15M | -3.64 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-01-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-01-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-01-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-01-10 | Downgrade | Stifel | Buy → Hold |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-10-01 | Downgrade | Truist | Buy → Hold |
| 2024-02-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-11-09 | Ripresa | Jefferies | Buy |
| 2022-10-17 | Iniziato | JP Morgan | Neutral |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2021-12-13 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-05 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-08-26 | Iniziato | Morgan Stanley | Overweight |
| 2021-01-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-07-17 | Iniziato | Robert W. Baird | Outperform |
| 2020-07-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-28 | Iniziato | SunTrust | Buy |
| 2020-04-22 | Iniziato | Wedbush | Outperform |
| 2019-10-14 | Iniziato | Guggenheim | Buy |
| 2019-10-14 | Iniziato | Jefferies | Buy |
| 2019-10-14 | Iniziato | Piper Jaffray | Overweight |
| 2019-10-14 | Iniziato | Stifel | Buy |
Mostra tutto
Igm Biosciences Inc Borsa (IGMS) Ultime notizie
IGM Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
IGM Biosciences (IGMS) to Release Earnings on Wednesday - MarketBeat
IGM Biosciences (IGMS) to Release Quarterly Earnings on Wednesday - Defense World
Layoff Tracker: IGM Axes 80% of Workforce - BioSpace
IGM Biosciences says it is dropping development of imvotamab - The Pharma Letter
IGM Biosciences ends agreement with Sanofi - Investing.com Australia
IGM Biosciences ends agreement with Sanofi By Investing.com - Investing.com South Africa
IGM Biosciences Ends Genzyme Collaboration, Cuts Workforce - TipRanks
Price T Rowe Associates Inc. MD Sells 445,260 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat
Renaissance Technologies LLC Raises Stock Holdings in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Stock Price Down 1.5%Here's Why - MarketBeat
IGM Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
IGM Biosciences, Inc. (NASDAQ:IGMS) Shares Bought by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Igm biosciences principal accounting officer sells $1,907 in stock - MSN
Q1 Biopharma Layoffs Hit California, Massachusetts Hard - BioSpace
IGMS stock touches 52-week low at $1 amid sharp annual decline - Investing.com
IGMS stock touches 52-week low at $1 amid sharp annual decline By Investing.com - Investing.com South Africa
IGM Bio stock slips as Bank of America downgrades (IGMS:NASDAQ) - Seeking Alpha
Short Interest in IGM Biosciences, Inc. (NASDAQ:IGMS) Decreases By 19.3% - MarketBeat
IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
IGMS stock plunges to 52-week low at $1.14 amid market challenges - Investing.com Australia
IGMS stock plunges to 52-week low at $1.14 amid market challenges By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Buys 9,441 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9%What's Next? - MarketBeat
IGM Biosciences stock plunges to 52-week low of $1.59 - MSN
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Rating of "Reduce" by Brokerages - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $5.50 Consensus PT from Brokerages - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9% – Here’s Why - Defense World
Sanofi Advances Immunology Ambitions With Dren Deal - insights.citeline.com
IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock By Investing.com - Investing.com Australia
IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 By Investing.com - Investing.com South Africa
IGM Biosciences chief business officer sells $5,549 in stock By Investing.com - Investing.com South Africa
IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock - Investing.com India
IGM Biosciences chief business officer sells $5,549 in stock - Investing.com India
IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 - Investing.com India
Igm biosciences officer sells shares worth $2,092 - Investing.com India
Igm biosciences officer sells shares worth $2,092 By Investing.com - Investing.com Australia
Igm Biosciences Inc Azioni (IGMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):